1 Thompson PD, Clarkson P, Karas RH. St atinassociated

myopathy[J]. JAMA, 2003, 289:1681-1690.

2 Tisha R. Narrative review:statin-related myopathy[J].

Ann Intern Med, 2009, 150:858-868.

3 Herman RJ. Drug interactions and the statins[J].

CMAJ, 1999, 161:1281-1286.

4 Folzenlogen D. A case of atorvastatin combined

toxic myopathy and inflammatory myositis[J]. J Clin

Rheumatol, 2001, 7:340-345.

5 Ertas FS, Ertas NM, Atmaca Y, et al. Unrecognized side

effect of statin treatment:unilateral blepharoptosis[J].

Ophthal Plast Reconstr Surg, 2006, 22:222-224.

6 Asbach P, Paetsch I, Stawowy P, et al. Statinassociated

focal myositis[J]. Int J Cardiol, 2009,

133:e33-e34.

7 Marusic S, Lisicic A, Horvatic I, et al. Atorvastatinrelated

rhabdomyolysis and acute renal failure in a

genetically predisposed patient with potential drugdrug

interaction[J]. Int J Clin Pharm, 2012, 34:825-827.

8 Gabb GM, Vitry A, Limaye V, et al. Serious statinassociated

myotoxicity and rhabdomyolysis in

Aboriginal and Torres Strait Islanders:a case series[J].

Intern Med J, 2013, 43:987-992.

9 Ram R, Swarnalatha G, Ramesh V, et al. Rhabdomyolysis

induced acute renal failure secondary to

statins[J]. Indian J Nephrol, 2013, 23:211-213.

10 Famularo G, Gasbar rone L, Galluzzo M, et al.

Atorvastatin-associated necrotising inf lammatory

myopathy[J]. Clin Exp Rheumatol, 2012, 30:981.

11 Ga r cia -Es t eve z DA. Myopat hy i n a n elde rly

patient:case report[J]. Reactions, 2013, 1462:12-27.

12 Rando LP, Cording SA, Newnham HH. Successful

reintroduction of statin therapy after myositis:was

there another cause?[J]. Med J Aust, 2004, 180:472-

473.

13 Ma cKay JW, Fe ne ch ME, My i nt KS. Ac ut e

rhabdomyolysis caused by combination therapy with

atorvastatin and warfarin[J]. Br J Hosp Med(Lond),

2012, 73:106-107.

14 Patel AM, Shar iff S, Bailey DG, et al. Statin

toxicity from macrolide antibiotic coprescription:a

population-based cohort study[J]. Ann Intern Med,

2013, 158:869-876.

15 Newman CB, Palmer G, Silbershatz H, et al. Safety

of atorvastatin derived from analysis of 44 completed

trials in 9,416 patients[J]. Am J Cardiol, 2003, 92:670-

676.

16 Al-Omran M, Mamdani MM , Lindsay TF, et al.

Suboptimal use of statin therapy in elderly patients

with atherosclerosis:A population-based study[J].

Vasc Surg, 2008, 48:607-612.

17 Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS

Guidelines for the management of dyslipidaemias:The

Task Force for the management of dyslipidaemias

of the European Society of Cardiology (ESC) and

the European Atherosclerosis Society (EAS)[J].

Atherosclerosis, 2011, 217:3-46.

18 Amarenco P, Goldstein LB, Szarek M, et al. Effects of

intense low-density lipoprotein cholesterol reduction

in patients with stroke or transient ischemic attack:The

Stroke Prevention by Aggressive Reduction in

Cholesterol Levels (SPARCL) Trial[J]. Stroke, 2007,

38:3198-3204.

19 Naci H, Brugts JJ, Fleurence R, et al. Comparative

effects of statins on major cerebrovascular events:a

multiple-t reatments meta-analysis of placebocontrolled

and active-comparator trials[J]. QJM, 2013,

106:299-306.

20 杨兴义, 陈娟娟, 李淑梅. 阿托伐他汀对高龄患者动脉

粥样硬化的影响及安全性研究[J]. 中华老年医学杂

志, 2012, 31:974-976.

21 Mashayekhi SO, Ghandforoush-Sattari M, Baghdadchi

ME, et al. Patients report of statains use and sideeffcts

in a sample of hospitalized cardiac patients in

the Istramic Republic of Iran[J]. East Mediterr Health

J, 2011, 17:460-464.

22 他汀类药物防治缺血性卒中/短暂性脑缺血发作专家

共识组. 他汀类药物防治缺血性卒中/短暂性脑缺血发

作专家共识[J]. 中国卒中杂志, 2013, 8:565-575.